BACKGROUND: Malignant hyperthermia (MH) is a fatal autosomal dominant pharmacogenetic disorder characterized by skeletal muscle hypertonicity that causes a sudden increase in body temperature after exposure to common anesthetic agents. The disease is genetically heterogeneous, with mutations in the gene encoding the skeletal muscle ryanodine receptor (RYR1) at 19q13.1 accounting for up to 80% of the cases. To date, at least 42 RYR1 mutations have been described that cause MH and/or central core disease. Because the RYR1 gene is huge, containing 106 exons, molecular tests have focused on the regions that are more frequently mutated. Thus the causative defect has been identified in only a fraction of families as linked to chromosome 19q, whereas in others it remains undetected. METHODS: We used denaturing HPLC (DHPLC) to analyze the RYR1 gene. We set up conditions to scan the 27 exons to identify both known and unknown mutations in critical regions of the protein. For each exon, we analyzed members from 52 families with positive in vitro contracture test results, but without preliminary selection by linkage analysis. RESULTS: We identified seven different mutations in 11 MH families. Among them, three were novel MH alleles: Arg44Cys, Arg533Cys, and Val2117Leu. CONCLUSION: Because of its sensitivity and speed, DHPLC could be the method of choice for the detection of unknown mutations in the RYR1 gene.
BACKGROUND: Malignant hyperthermia (MH) is a fatal autosomal dominant pharmacogenetic disorder characterized by skeletal muscle hypertonicity that causes a sudden increase in body temperature after exposure to common anesthetic agents. The disease is genetically heterogeneous, with mutations in the gene encoding the skeletal muscle ryanodine receptor (RYR1) at 19q13.1 accounting for up to 80% of the cases. To date, at least 42 RYR1 mutations have been described that cause MH and/or central core disease. Because the RYR1 gene is huge, containing 106 exons, molecular tests have focused on the regions that are more frequently mutated. Thus the causative defect has been identified in only a fraction of families as linked to chromosome 19q, whereas in others it remains undetected. METHODS: We used denaturing HPLC (DHPLC) to analyze the RYR1 gene. We set up conditions to scan the 27 exons to identify both known and unknown mutations in critical regions of the protein. For each exon, we analyzed members from 52 families with positive in vitro contracture test results, but without preliminary selection by linkage analysis. RESULTS: We identified seven different mutations in 11 MH families. Among them, three were novel MH alleles: Arg44Cys, Arg533Cys, and Val2117Leu. CONCLUSION: Because of its sensitivity and speed, DHPLC could be the method of choice for the detection of unknown mutations in the RYR1 gene.
Authors: Barbara W Brandom; Saiid Bina; Cynthia A Wong; Tarina Wallace; Mihaela Visoiu; Paul J Isackson; Georgirene D Vladutiu; Nyamkhishig Sambuughin; Sheila M Muldoon Journal: Anesth Analg Date: 2013-04-04 Impact factor: 5.108
Authors: Natalia Kraeva; Elena Zvaritch; Ann E Rossi; Sanjeewa A Goonasekera; Hilal Zaid; Wanda Frodis; Alexander Kraev; Robert T Dirksen; David H Maclennan; Sheila Riazi Journal: Neuromuscul Disord Date: 2012-11-24 Impact factor: 4.296
Authors: Kerstin Hoppe; Guido Hack; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Alberto Zullo; Antonella Carsana; Werner Klingler Journal: Sci Rep Date: 2016-09-20 Impact factor: 4.379
Authors: Tran-Thuy Nguyen; Ngoc-Thanh Le; Thuy-Mau Thi Nguyen; Huy-Hoang Nguyen; Kim-Lien Thi Nguyen; Long Doan Dinh; The-Binh Nguyen; Anh Tien Do; Cong Huu Nguyen; Trung-Hieu Nguyen; Hong-Nhung Thi Pham; Thom Thi Vu Journal: Ann Med Surg (Lond) Date: 2019-11-06
Authors: Werner Klingler; Sebastian Heiderich; Thierry Girard; Elvira Gravino; James Ja Heffron; Stephan Johannsen; Karin Jurkat-Rott; Henrik Rüffert; Frank Schuster; Marc Snoeck; Vincenzo Sorrentino; Vincenzo Tegazzin; Frank Lehmann-Horn Journal: Orphanet J Rare Dis Date: 2014-01-16 Impact factor: 4.123